Exelixis’ Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYX® (cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma | Business Wire

Exelixis’ Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYX® (cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma | Business Wire: Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen received validation of the application for variation to the CABOMETYX® (cabozantin